A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Date Added
December 10th, 2020
PRO Number
Pro00105462
Researcher
Patrick Flume

List of Studies


Keywords
Coronavirus, Vaccine
Summary

The purpose of this study is to see if a vaccine that is being developed to prevent people from getting sick with COVID-19 is safe and effective and also to see how well it is tolerated. Participants will receive a shot of either the vaccine or a placebo twice: once on Day 1 and a booster shot on Day 57. Participants will have blood drawn several times over a 24 month period to assess the immune system response (how your body fights off the virus). Participation will last about 24 months. Participants will receive payment in return for their time and effort.

Institution
MUSC
Recruitment Contact
Amy Chamberlain
843-792-3162
chambeam@musc.edu

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)

Date Added
October 18th, 2016
PRO Number
Pro00059616
Researcher
Bhavadharini Ramu

List of Studies


Keywords
Cardiovascular, Heart, Vaccine
Summary

INVESTED is a multi-site trial comparing high-dose (60 μg per vaccine viral strain) trivalent influenza vaccine to standard-dose (15 μg per viral strain) quadrivalent influenza vaccination for up to three influenza seasons in high-risk cardiovascular disease patients with a history of myocardial infarction in the previous 12 months OR history of heart failure hospitalization in the previous 24 months. Subjects will be randomly assigned to receive either the high-dose or standard-dose vaccine.

Institution
MUSC
Recruitment Contact
Ricardo Cantu
843-792-8894
cantur@musc.edu



-- OR --